What is Hologic Diagenode?
Headquartered in Wallonia, Belgium, and established in 2003, Diagenode operates as a specialized subsidiary of Hologic, focusing on the development of sample preparation solutions for next-generation sequencing (NGS), proteomics, and epigenetics. The company serves as a vital link in the research value chain, offering proprietary technologies that streamline laboratory workflows and enhance data reproducibility. As a key component of Hologic's broader diagnostic and research portfolio, Diagenode leverages deep technical expertise to address the growing demand for high-throughput molecular analysis, positioning itself as an essential partner for academic and clinical research institutions worldwide.
How much funding has Hologic Diagenode raised?
Hologic Diagenode has raised a total of $8.5M across 1 funding round:
Other Financing Round
$8.5M
Other Financing Round (2016): $8.5M with participation from Societe Regionale d'Investissement de Wallonie, Epimede SA, Capricorn Health-tech Fund NV, SpinVenture, SRIW SA, and OBI SA
Key Investors in Hologic Diagenode
Wallonie Entreprendre
Wallonie Entreprendre is the economic and financial tool of Wallonia, dedicated to supporting the entrepreneurial fabric of the region. The organization provides various services including financing, guarantees, and expertise to foster sustainable growth and job creation.
Capricorn Health-tech Fund NV
A specialized venture capital firm focusing on early-to-growth stage investments in the healthcare and life sciences sectors, providing strategic guidance to innovative technology companies.
Societe Regionale d'Investissement de Wallonie
A regional investment entity focused on fostering industrial development and economic stability within the Wallonia region through targeted equity and debt financing.
What's next for Hologic Diagenode?
With the support of its recent capital infusion, Hologic Diagenode is poised to accelerate its research and development initiatives, particularly in the expansion of its epigenetics and NGS product suites. The strategic focus will likely shift toward scaling manufacturing capabilities and deepening market penetration in high-growth regions. By integrating its specialized sample preparation expertise with Hologic's extensive distribution network, the company is well-positioned to capitalize on the increasing complexity of genomic research. Future growth will be driven by the continued adoption of its automated solutions, which are increasingly critical for clinical diagnostics and precision medicine applications, ensuring long-term sustainability and competitive advantage in the life sciences sector.
See full Hologic Diagenode company page
